Johnson & Johnson

Conclusion

Johnson & Johnson has successfully transitioned from a diversified healthcare conglomerate to a focused Pharmaceutical and MedTech pure-play. The Kenvue separation, while causing short-term EPS volatility, has streamlined the business and improved profitability. The company is currently delivering:

• Stable 6-7% organic revenue growth;

• Expanding operating and EBITDA margins (despite some gross margin pressure);

• Strong double-digit adjusted EPS growth;

• A healthy balance sheet with a manageable interest burden.

However, investors should be aware of the one-time items that can cause significant earnings volatility on a reported basis, and should focus on adjusted earnings for a true picture of operating performance. The Q1 2026 results suggest the momentum is continuing into 2026, albeit with some headwinds from interest costs and litigation expenses.

=====

Looking across Johnson & Johnson's income statements over the past five years, a clear story of strategic transformation and resilient growth emerges. The most significant factor in interpreting these trends is the separation of its Consumer Health business into an independent company, Kenvue, which was completed in August 2023. Since then, J&J has focused exclusively on its two core pillars: Innovative Medicine (primarily pharmaceuticals) and MedTech (medical devices). This structural change is why 2021-2022 revenues appear much larger in the table: those years included the consumer division, which was later removed and reported as "Discontinued Operations." From 2023 onward, the presented "Sales/Revenue" figures represent this streamlined, higher-margin entity.

On a continuing operations basis, Johnson & Johnson has demonstrated consistent, if unspectacular, growth. Revenues increased from approximately $85.2 billion in 2023 to $94.2 billion in 2025, representing a compound annual growth rate (CAGR) in the low-to-mid single digits. This expansion has been driven by the company's powerful oncology franchise, led by Darzalex, a multiple myeloma drug that alone generated over $14 billion in sales in 2025, rising 22%. This growth has been strong enough to offset the loss of exclusivity (LOE) for former blockbuster Stelara, which began to impact 2025 results. The MedTech segment has also been a reliable contributor, posting organic sales growth of 4.3% for the full year 2025 and strong performances in cardiovascular surgery.

The focus on these high-margin segments has a direct and positive impact on J&J's profitability. Over the five-year period, the company has consistently maintained a gross profit margin between 67% and 69%, showcasing its strong pricing power and efficient cost management. More notably, the operating leverage inherent in its business is evident in the growth of EBIT and EBITDA, which have risen faster than revenue. The surge in Pretax Income and Net Income in 2025 to $32.6 billion and $26.8 billion, respectively, represents a dramatic 95% and 90% year-over-year growth. While this is partly attributable to a favorable swing in unusual expenses (likely one-time gains or litigation reserve releases), the underlying business is clearly firing on all cylinders, as reflected in the net margin jumping to 28.46% in 2025, up from 15.8% the year before. This improved profitability translated directly to shareholders, with diluted EPS rising from $5.79 in 2024 to $11.03 in 2025.

This momentum has continued into the most recent reporting period. In the first quarter of 2026, J&J reported a **9.9% increase in sales to $24.1 billion**, though net earnings of $5.2 billion were significantly lower than the $11.0 billion reported in the same quarter of 2025 due to the one-off items that had inflated that previous quarter. Looking at the quarterly trend throughout 2025, revenues climbed steadily from $21.9 billion in Q1 to $24.6 billion in Q4, demonstrating strong sequential growth and a robust end to the year. However, the quarterly data also reveals some noise in gross margins, which have fluctuated between 66.8% and 69.7%, and in SG&A expenses, which saw a notable spike in Q4 2025 before normalizing in Q1 2026. These variations are often typical for large multinationals and can be attributed to factors like product mix, marketing campaigns, and the timing of R&D investments.

Looking forward, Johnson & Johnson's management has expressed confidence in the company's trajectory. The 2026 outlook is optimistic, with revenue guidance raised to a range of $100.3 billion to $101.3 billion and adjusted EPS guidance raised to $11.45-$11.65. This confidence is rooted in the expectation that growth will accelerate in both the Innovative Medicine and MedTech segments. In summary, J&J has successfully navigated a major corporate restructuring and is now a more focused, profitable, and growth-oriented company. While historical comparisons are complicated by the Kenvue spin-off, the recent annual and quarterly results clearly paint a picture of a healthcare giant effectively leveraging its strongest divisions to deliver robust shareholder value and a promising outlook.